Eric Faulkner, RTI Health Solutions Director of US Market Access and Reimbursement, will speak at the Phacilitate Cell & Gene Therapy Forum to be held in Washington, DC on January 25-27, 2010
(http://www.phacilitate.co.uk/cgtherapy). This forum will assemble stakeholders from around the globe to discuss key issues related to the development, adoption and diffusion of emerging cell and gene therapies.
Mr. Faulkner will provide an opening address entitled Addressing the Feasibility of Cell and Gene Therapies as Commercial Entities in the Evolving Health Care Environment. The opening address will cover the following key issues:
- What prices can traditionally high-value biologics expect to reach in the evolving healthcare marketplace, and what benefit level will be required to achieve them?
- Will functional improvement be enough to gain top prices, or will such therapies need to have an impact on mortality?
- How commercially feasible are 'personalized medicines' given ongoing healthcare reform?
Mr. Faulkner will also serve as a reimbursement expert in the following panel discussion: How do Payers and Physicians Make Their Product Choice Decisions? How Do They Assess Value? What Can Industry Learn?
Eric’s responsibilities at RTI Health Solutions (RTI-HS) involve evaluation of US and international pricing and reimbursement issues, health technology assessment practices, product reimbursement and commercialization strategies and changing health policy. He has recently served as an expert advisor to the Personalized Medicine Subcommittee of the President’s Council of Advisors on Science and Technology and is serving as the Chair of the Personalized Medicine Special Interest Group of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and on the Leadership Committee of the Global Health Care Reimbursement Systems & Decision Processes Working Group of ISPOR, including the working groups on HTA for pharmaceuticals and on HTA for medical devices and diagnostics. Eric is also a member of the Leadership Committee of the Business Models and Reimbursement Working Group of the International Society for Cellular Therapy (ISCT).
In addition to responsibilities at RTI, Mr. Faulkner also serves as the Executive Director of the Genomic Biotech Institute (GBI) of the National Association of Managed Care Physicians (NAMCP) and Editor-in-Chief of the GBI special section of the Journal of Managed Care Medicine, Genomics and Biotechnology. Eric also serves as an adjunct Assistant Professor for the Institute for Pharmacogenomics and Individualized Therapy at the Eshelman School of Pharmacy - University of North Carolina at Chapel Hill.